Amarin Corp Plc (AMRN)

[FlyFishingStocks]

Zumantu offered this regarding anti-cancer efficacy of V via free fatty acid receptor 4

One of the key targets for cancer prevention (or treatment) is via the inhibition of the tumour growth by stopping the division of cancer (or pre-cancer) cells. Omega-3s are well documented for their anti-inflammatory and anti-proliferative properties and in this study EPA exhibited its anti-cancer properties by binding to FFA4 (free fatty acid receptor 4), suppressing proliferation by triggering signals that inhibit cancer cell growth. [2] Interestingly, and in keeping with other studies of this nature, this was a characteristic attributed to EPA rather than DHA. Whilst this study was performed in vitro, and caution should be observed with regard to relating these findings to human intervention, it does provide valuable mechanistic information relating to the anti-inflammatory role of EPA. Indeed, the action of EPA as an anti-inflammatory cyclooxygenase (COX)-2 inhibitor has been demonstrated as a potentially effective chemopreventive tool against colorectal cancer in both animals [3] and humans [4] and encouragingly is now at phase III trial stage. The primary aim of the ongoing trial is to determine if 2g EPA daily (as rTG) prevents the development of colorectal adenomas, either alone or in combination with aspirin. [5] If EPA is shown to be an effective way to reduce bowel polyps, it may also reduce future bowel cancer risk, thus opening up the same potential as an intervention tool for prostate cancer prevention.

http://igennus.com/practitioner-blog/new-in-vitro-study-shows-encouraging-link-between-epa-and-prostate-cancer-prevention/

one of these days we are going to be surprised by trial findings.